Journal article

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

Abstract:: Background
Rift Valley fever is a viral epidemic illness prevalent in Africa that can be fatal or result in debilitating sequelae in humans. No vaccines are available for human use. We aimed to evaluate the safety and immunogenicity of a non-replicating simian adenovirus-vectored Rift Valley fever (ChAdOx1 RVF) vaccine in humans.
Methods
We conducted a phase 1, first-in-human, open-label, dose-escalation trial in healthy adults aged 18-50 years at th... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Jenkin, D., Wright, D., Folegatti, P. M., Platt, A., Poulton, I., Lawrie, A., Tran, N., Boyd, A., Turner, C., Gitonga, J. N., Karanja, H. K., Mugo, D., Ewer, K. J., Bowden, T. A., Gilbert, S. C., Charleston, B., Kaleebu, P., Hill, A. V. S., & Warimwe, G. M. (2023). Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial. Lancet Infectious Diseases, 23(8), 956–964.

MLA Style

Jenkin, D, et al. “Safety and Immunogenicity of a ChAdOx1 Vaccine against Rift Valley Fever in UK Adults: an Open-Label, Non-Randomised, First-in-Human Phase 1 Clinical Trial.” Lancet Infectious Diseases, vol. 23, no. 8, 2023, pp. 956–64.

Chicago Style

Jenkin, D, D Wright, PM Folegatti, et al. 2023. “Safety and Immunogenicity of a ChAdOx1 Vaccine against Rift Valley Fever in UK Adults: an Open-Label, Non-Randomised, First-in-Human Phase 1 Clinical Trial.” Lancet Infectious Diseases 23 (8): 956–64.
Print

Access Document

Files:: Jenkin_et_al_2023_Safety_and_immunogenicity.pdf

(Preview, Version of record, pdf, 523.8KB, Terms of use)

Jenkin_et_al_2023_Supplementary_material.zip

(Supplementary materials, zip, 2.6MB, Terms of use)

Publisher copy:: 10.1016/s1473-3099(23)00068-3

Authors

+ Jenkin, D More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author
ORCID:: 0000-0003-3088-310X

+ Wright, D More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Folegatti, PM More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Platt, A More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Poulton, I More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

More authors...

+ Wellcome Trust More from this funder

Funder identifier:: https://ror.org/029chgv08
Grant:: 203077/B/16/Z; 203077_Z_16_Z; 203077/Z/16/Z

+ Department of Health and Social Care More from this funder

Funder identifier:: https://ror.org/03sbpja79
Grant:: 16/107/02

+ National Institute for Health and Care Research More from this funder

Funder identifier:: https://ror.org/0187kwz08
Grant:: 16/107/03

+ Oak Foundation More from this funder

Funder identifier:: https://ror.org/006ss0h52

Publisher:: Elsevier
Journal:: Lancet Infectious Diseases More from this journal
Volume:: 23
Issue:: 8
Pages:: 956-964
Place of publication:: United States
Publication date:: 2023-04-13
Acceptance date:: 2023-01-30
DOI:: 10.1016/s1473-3099(23)00068-3
EISSN:: 1474-4457
ISSN:: 1473-3099
Pmid:: 37060917

Language:: English
Pubs id:: 1338470
Local pid:: pubs:1338470
Source identifiers:: W4365457063
Deposit date:: 2026-04-01
ARK identifier:: ark:/29072/ora_5d8e6484b6014d96bcde8a3046750061

Terms of use

Copyright holder:: Jenkin et al.
Copyright date:: 2023
Rights statement:: © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP